Results 61 to 70 of about 28,261 (176)
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff +2 more
wiley +1 more source
EBOV GP–specific IFNγ producing T cell responses (IFNγ ELISpot).
, 2021 EBOV GP, Ebola virus glycoprotein; ELISpot, enzyme-linked immunospot; IFNγ, interferon gamma. (DOCX)
Zacchaeus Anywaine (3578855) +22 more
core +1 more source
Interdisciplinary Medicine, Volume 4, Issue 3, May 2026.This review illustrates how scientists engineer exosomes by hijacking the cell's own cargo‐sorting machinery. These strategies efficiently load therapeutic molecules into natural vesicles, creating powerful next‐generation drug delivery systems (Created with BioGDP.com).
Huanrong Zhu +6 more
wiley +1 more source
EBOV seroprevalence estimates using different assays in DRC.
, 2023 EBOV seroprevalence estimates using different assays in DRC.
Ynke Larivière (16920398) +14 more
core +1 more source
Small Molecule Inhibition of Mononegavirales RNA Polymerases
Journal of Medical Virology, Volume 98, Issue 5, May 2026.ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Claire R. Cao +3 more
wiley +1 more source
Comparison of EBOV and MARV pathophysiology over time.
, 2022 EBOV, Ebola virus; MARV, Marburg virus; NHP, nonhuman primate.
Christopher D. Kane (8592750) +4 more
core +1 more source
Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
PLoS PathogensThe Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential.
Fan Bu +13 more
doaj +1 more source
Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus
Viruses, 2019 Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013−2016 West African outbreak.
Mable Chan +7 more
doaj +1 more source
Cohorts of immature Pteropus bats show interannual variation in Hendra virus serology
Journal of Animal Ecology, Volume 95, Issue 3, Page 521-537, March 2026.Pteropus bat with offspring, photo taken by Manuel Ruiz‐Aravena. Abstract Understanding the drivers of seasonal disease outbreaks remains a fundamental challenge in disease ecology. Periodic outbreaks can be driven by several seasonally varying factors, including pulses of susceptible individuals through births, changes in host behaviour and social ...
Daniel E. Crowley +24 more
wiley +1 more source
Determination of neutralising antibody activity in an EBOV GP psVNA.
, 2021 EBOV GP, Ebola virus glycoprotein; psVNA, pseudovirion neutralisation assay. (DOCX)
Zacchaeus Anywaine (3578855) +22 more
core +1 more source